First Eagle Investment Management LLC Has $2.09 Billion Stock Holdings in Becton, Dickinson and Company $BDX

Key Points

• First Eagle Investment Management increased its BDX stake by 15.8% in the second quarter, owning 13.82 million shares valued at approximately $2.09 billion, or 5.01% of Becton, Dickinson and Company.
• Becton, Dickinson reported quarterly revenue of $4.98 billion and adjusted earnings of $3.23 per share, exceeding analyst estimates, while revenue grew 5.4% year over year. The company reaffirmed fiscal 2026 EPS guidance of $12.62–$12.72.
• BDX shares were trading near $184.78, and the company announced a quarterly dividend of $1.05 per share, implying a 2.3% annualized yield. Analysts’ consensus rating was “Hold,” with an average price target of $187.67.

First Eagle Investment Management LLC raised its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 15.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,815,335 shares of the medical instruments supplier's stock after purchasing an additional 1,887,224 shares during the quarter. Becton, Dickinson and Company makes up about 2.3% of First Eagle Investment Management LLC's portfolio, making the stock its 12th biggest holding. First Eagle Investment Management LLC owned 5.01% of Becton, Dickinson and Company worth $2,090,675,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in BDX. California State Teachers Retirement System increased its holdings in Becton, Dickinson and Company by 14,668.6% during the second quarter. California State Teachers Retirement System now owns 69,907,953 shares of the medical instruments supplier's stock worth $10,579,171,000 after buying an additional 69,434,598 shares during the last quarter. Studio Investment Management LLC lifted its stake in Becton, Dickinson and Company by 11.2% in the second quarter. Studio Investment Management LLC now owns 11,872 shares of the medical instruments supplier's stock valued at $1,797,000 after acquiring an additional 1,193 shares during the last quarter. Wedmont Private Capital bought a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $206,000. Kintra Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $384,000. Finally, HB Wealth Management LLC increased its stake in shares of Becton, Dickinson and Company by 8.5% during the 2nd quarter. HB Wealth Management LLC now owns 31,456 shares of the medical instruments supplier's stock worth $4,760,000 after purchasing an additional 2,468 shares during the last quarter. Institutional investors own 86.97% of the company's stock.

Insider Buying and Selling at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the business's stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares of the company's stock, valued at $3,717,022.80. The trade was a 0.83% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the firm's stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the transaction, the executive vice president directly owned 14,856 shares in the company, valued at $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 9,105 shares of company stock valued at $1,590,208. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Trading Up 0.0%

Shares of NYSE:BDX opened at $184.78 on Monday. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $193.07. The business has a 50 day moving average of $170.05 and a 200-day moving average of $160.58. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The stock has a market cap of $50.91 billion, a PE ratio of 55.66, a P/E/G ratio of 13.02 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter last year, the company earned $3.68 earnings per share. The firm's quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company's payout ratio is presently 126.51%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on BDX shares. The Goldman Sachs Group cut their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating for the company in a research note on Wednesday, May 27th. Bank of America boosted their price target on Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Monday, August 31st. Royal Bank Of Canada upped their price objective on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research note on Thursday, August 13th. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research report on Monday, July 6th. Finally, Barclays lifted their target price on Becton, Dickinson and Company from $202.00 to $204.00 and gave the stock an "overweight" rating in a research note on Monday, May 11th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $187.67.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.